Ergomed (XTRA:2EM) - Aktienkurs, Nachrichten und Analyse

2EM Aktienübersicht

Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally.

Über das Unternehmen

2EM fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

Belohnungen

46.5% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 13.13% pro Jahr

Die Erträge stiegen im vergangenen Jahr um 18.2%

Risikoanalyse

Aktien sind hochgradig illiquide

Die Aktionäre wurden im vergangenen Jahr verwässert

Ergomed plc Wettbewerber

Gerresheimer

XTRA:GXI

€3.3b

SCHOTT Pharma KGaA

XTRA:1SXP

€4.1b

Sartorius

XTRA:SRT3

€15.2b

Formycon

XTRA:FYB

€840.6m

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Ergomed
Historical stock prices
Current Share Price	UK£11.00
52 Week High	UK£16.10
52 Week Low	UK£11.00
Beta	0.86
1 Month Change	0%
3 Month Change	-3.85%
1 Year Change	-5.98%
3 Year Change	113.18%
5 Year Change	461.22%
Change since IPO	349.90%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	2EM	DE Life Sciences	DE Markt
7D	0%	-3.4%	-1.8%
1Y	-6.0%	-13.9%	1.7%

Rendite im Vergleich zur Industrie: 2EM übertraf die Branche German Life Sciences, die im vergangenen Jahr eine Rendite von -13.1 erzielte.

Rendite vs. Markt: 2EM hinter dem Markt German zurück, der im vergangenen Jahr eine Rendite von 5.2 erzielte.

Preisvolatilität

Is 2EM's price volatile compared to industry and market?
2EM volatility
2EM Average Weekly Movement	n/a
Life Sciences Industry Average Movement	5.8%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.4%
10% least volatile stocks in DE Market	2.6%

Stabiler Aktienkurs: 2EM hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von 2EM im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1997	1,400	n/a	www.ergomedplc.com

Ergomed plc's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Ergomed im Vergleich zum Marktanteil des Unternehmens?
2EM grundlegende Statistiken
Marktanteil	€567.10m
Gewinn(TTM)	€17.43m
Umsatz(TTM)	€169.00m

32.5x

Kurs-Gewinn-Verhältnis

3.4x

Kurs-Umsatz-Verhältnis

Ist 2EM zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
2EM Gewinn- und Verlustrechnung (TTM)
Einnahmen	UK£145.26m
Kosten der Einnahmen	UK£64.71m
Bruttogewinn	UK£80.55m
Sonstige Ausgaben	UK£65.57m
Umsatz	UK£14.98m

Zuletzt gemeldete Gewinne

Dec 31, 2022

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	0.30
Bruttomarge	55.45%
Nettogewinnspanne	10.31%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich 2EM auf lange Sicht entwickelt?

Historische Performance und Vergleiche

2EM Aktienübersicht

Belohnungen

Risikoanalyse

Ergomed plc Wettbewerber

XTRA:GXI

€3.3b

XTRA:1SXP

€4.1b

XTRA:SRT3

€15.2b

XTRA:FYB

€840.6m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Recent updates

Ergomed Submits an Application London Stock Exchange in Relation to the Cancellation of the Admission to Trading of its Shares on AIM, Expects to Take Place on 14 November 2023

Permira Advisers Ltd. completed the acquisition of Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others.

Ergomed Confirms Expected Scheme Timetable

Ergomed plc (AIM:ERGO) acquired Panacea Pharma Projects Limited from Stuart Colligon.

Permira Advisers Ltd. entered into a scheme of arrangement to acquire Ergomed plc (AIM:ERGO) from Amati Global Investors Ltd. and others for approximately £700 million.

Ergomed plc to Report Q2, 2023 Results on Sep 26, 2023

Ergomed plc Provides Earnings Forecast for the Full Year 2023

Ergomed plc, Annual General Meeting, Jun 22, 2023

Full year 2022 earnings released: EPS: UK£0.30 (vs UK£0.26 in FY 2021)

High number of new and inexperienced directors

Ergomed plc to Report Fiscal Year 2022 Results on Mar 21, 2023

High number of new and inexperienced directors

Ergomed plc Announces Board Changes, Effective 3 February 2023

Ergomed plc Announces Executive Changes

Ergomed plc Announces Directorate Changes

Ergomed Announces Two Senior Appointments to its Executive Team

Ergomed Strengthens Executive Management Team

Ergomed Strengthens Executive Management Team

Now 21% undervalued after recent price drop

First half 2022 earnings released: EPS: UK£0.15 (vs UK£0.14 in 1H 2021)

Ergomed plc to Report First Half, 2022 Results on Sep 27, 2022

Investor sentiment improved over the past week

Ergomed plc Appoints Anne Whitaker as Independent Non-Executive Director

Full year 2021 earnings released: EPS: UK£0.26 (vs UK£0.20 in FY 2020)

Ergomed plc, Annual General Meeting, Jun 10, 2022

Less than half of directors are independent

Now 21% undervalued

Full year 2021 earnings released: EPS: UK£0.26 (vs UK£0.20 in FY 2020)

Investor sentiment improved over the past week

John Dawson, Cbe Joins the Board of Ergomed plc as Independent Non-Executive Director and Chair of the Audit Committee

Investor sentiment improved over the past week

Ergomed plc to Report Fiscal Year 2021 Results on Mar 29, 2022

Pharmaust Limited Engages Ergomed Clinical Research Ltd to Commence Clinical Trials Testing the Anti-Viral Effects of Monepantel

Ergomed plc (AIM:ERGO) acquired Adamas Consulting Ltd. at an enterprise value of £24.2 million.

Ergomed plc Provides Revenue Guidance for the Year Ended 31 December 2021

First half 2021 earnings released: EPS UK£0.14 (vs UK£0.089 in 1H 2020)

Investor sentiment improved over the past week

Non-Executive Director has left the company

Investor sentiment improved over the past week

Full year 2020 earnings released

New 90-day high: €14.15

Ergomed plc to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day high: €13.40

New 90-day high: €12.10

Ergomed plc (AIM:ERGO) acquired MedSource Consulting Inc. for $25 million.

New 90-day high: €9.76

New 90-day high: €9.58

New 90-day high - €7.68

New 90-day high - €6.86

Ergomed plc to Report First Half, 2020 Results on Sep 22, 2020

New 90-day high - €6.60

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Ergomed plc's Grundlagenzusammenfassung

32.5x

3.4x

Erträge &amp; Einnahmen

Erträge & Einnahmen